Racivir

Racivir
Systematic (IUPAC) name
	4-amino-5-fluoro-1-[(2S,5R)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-1,2-dihydropyrimidin-2-one
Clinical data
Routes of; administration	Investigational
Identifiers
CAS Number	137530-41-7
ATC code	none
PubChem	CID: 454858
ChemSpider	400521
NIAID ChemDB	005245
Chemical data
Formula	C8H10FN3O3S
Molecular mass	247.25 g/mol
	SMILES c1c(c(nc(=O)n1[C@H]2CS[C@H](O2)CO)N)F ;
	InChI InChI=1S/C8H10FN3O3S/c9-4-1-12(8(14)11-7(4)10)5-3-16-6(2-13)15-5/h1,5-6,13H,2-3H2,(H2,10,11,14)/t5-,6+/m1/s1 ; Key:XQSPYNMVSIKCOC-RITPCOANSA-N ;

Racivir is an experimental nucleoside reverse transcriptase inhibitor (NRTI), developed by Pharmasset for the treatment of HIV.^[1] It is the enantiomer of emtricitabine, a widely used NRTI, meaning that the two compounds are mirror images of each other.

Emtricitabine, the enantiomer of racivir and a widely used NRTI

References

This antiinfective drug article is a stub. You can help Wikipedia by expanding it.

Systematic (IUPAC) name

4-amino-5-fluoro-1-[(2S,5R)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-1,2-dihydropyrimidin-2-one
Clinical data
Routes of administration	Investigational
Identifiers
CAS Number	137530-41-7
ATC code	none
PubChem	CID: 454858
ChemSpider	400521
NIAID ChemDB	005245
Chemical data
Formula	C₈H₁₀FN₃O₃S
Molecular mass	247.25 g/mol
SMILES c1c(c(nc(=O)n1[C@H]2CS[C@H](O2)CO)N)F
InChI InChI=1S/C8H10FN3O3S/c9-4-1-12(8(14)11-7(4)10)5-3-16-6(2-13)15-5/h1,5-6,13H,2-3H2,(H2,10,11,14)/t5-,6+/m1/s1 Key:XQSPYNMVSIKCOC-RITPCOANSA-N